FDA Public Workshop Summary-Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs.

O'Shaughnessy E, Yasinskaya Y, Dixon C, Higgins K, Moore J, Reynolds K, Ampel NM, Angulo D, Blair JE, Catanzaro A, Galgiani JN, Garvey E, Johnson R, Larwood DJ, Lewis G, Purdie R, Rex JH, Shubitz LF, Stevens DA, Page SJ, Shukla SJ, Farley JJ, Nambiar S

Open source

DOI: 10.1093/cid/ciab904
Published: 2022 Jun 10
Container: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/cid/ciab904,
  title = {FDA Public Workshop Summary-Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs.},
  author = {O'Shaughnessy E and Yasinskaya Y and Dixon C and Higgins K and Moore J and Reynolds K and Ampel NM and Angulo D and Blair JE and Catanzaro A and Galgiani JN and Garvey E and Johnson R and Larwood DJ and Lewis G and Purdie R and Rex JH and Shubitz LF and Stevens DA and Page SJ and Shukla SJ and Farley JJ and Nambiar S},
  year = {2022},
  journal = {Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  doi = {10.1093/cid/ciab904},
  url = {https://doi.org/10.1093/cid/ciab904}
}

RIS

TY  - JOUR
TI  - FDA Public Workshop Summary-Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs.
AU  - O'Shaughnessy E
AU  - Yasinskaya Y
AU  - Dixon C
AU  - Higgins K
AU  - Moore J
AU  - Reynolds K
AU  - Ampel NM
AU  - Angulo D
AU  - Blair JE
AU  - Catanzaro A
AU  - Galgiani JN
AU  - Garvey E
AU  - Johnson R
AU  - Larwood DJ
AU  - Lewis G
AU  - Purdie R
AU  - Rex JH
AU  - Shubitz LF
AU  - Stevens DA
AU  - Page SJ
AU  - Shukla SJ
AU  - Farley JJ
AU  - Nambiar S
PY  - 2022
JO  - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
DO  - 10.1093/cid/ciab904
UR  - https://doi.org/10.1093/cid/ciab904
ER  -

APA

E, O., Y, Y., C, D., K, H., J, M., K, R., NM, A., D, A., JE, B., A, C., JN, G., E, G., R, J., DJ, L., G, L., R, P., JH, R., LF, S., DA, S., SJ, P., SJ, S., JJ, F., & S, N. (2022). FDA Public Workshop Summary-Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. https://doi.org/10.1093/cid/ciab904

Source records

pubmed · retrieved 2026-09-27T09:50:08.676Z